Evidence-based expert consensus on clinical management of safety of Bruton's tyrosine kinase inhibitors (2024).
Song Z, Jiang D, Yu L, Chen Y, Zhou D, Li Y, Wu D, Zhang L, Miao L, Ma J, Zhu J, Jing H, Zhao R, Steering Committee OBOT, Evidence-Based Pharmacy Professional Committee Of Chinese Pharmaceutical Association Cpa TCPATESG, Chinese Pharmaceutical Association Cpa HPPCO, Chinese Pharmacological Society Cps DOTDMO, Clinical Oncology Csco ECOLOCSO, Chinese Society Of Clinical Oncology Csco ECOLO, China Anti-Cancer Association Caca SOICO, Chinese Medical Association Cma CSOHO, Cross-Straits Medicine Exchange Association Smea HPPCO.
Song Z, et al. Among authors: steering committee obot.
Chin J Cancer Res. 2024 Jun 30;36(3):240-256. doi: 10.21147/j.issn.1000-9604.2024.03.02.
Chin J Cancer Res. 2024.
PMID: 38988488
Free PMC article.